Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)

Funding Opportunity PAR-14-292 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding

Related Links:

Called Winship at Midtown, the nearly $500 million building will consolidate cancer services and improve a patient's experience.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Abstract Human papillomaviruses (HPV) are small, double-stranded DNA viruses that cause cervical cancer, the second most lethal cancer among women in the world. Currently, two vaccines are on the market for preventing HPV-caused cervical cancers and warts. Both are virus-like particle (VLP)-based vaccines. However, these vaccines have limitations; they are costly, have an invasive route of administration, require trained personnel to administer, need cold chain storage to preserve them, and most of all, they are preventive vaccines that do not have curative effects. Therefore, it is necessary to develop therapeuti...
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Tags: J Pharm Pharm Sci Source Type: research
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Article Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Article Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Perspective Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Trends and Innovations Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Snapshot Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Best of the Rest Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Quiz Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Bone and Joint in Brief Source Type: news
More News: Brain | Chemistry | Contracts | Funding | Grants | Investigational New Drugs | Neurology | Research | Study | Toxicology